CHARACTERIZATION OF KAINATE & AMPA RECEPTOR ANTAGONIST

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$49,669.00
Award Year:
1991
Program:
SBIR
Phase:
Phase I
Contract:
n/a
Award Id:
16768
Agency Tracking Number:
16768
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
6200 Freeport Ctr, Baltimore, MD, 21224
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Edward Karbon Jr
(301) 558-7000
Business Contact:
() -
Research Institute:
n/a
Abstract
STROKE IS THE MOST PROMINENT CNS DISORDER IN THE UNITED STATES AS WELL AS THE LEADING CAUSE OF DISABILITY AND THE THIRD LEADING CAUSE OF DEATH. HOWEVER, THERE ARE NO EFFECTIVE TREATMENTS AVAILABLE TO PREVENT OR REDUCE NEURONAL DAMAGE RESULTING FROM STROKE OR OTHER FORMS OF CEREBRAL ISCHEMIA. EPILEPSY IS THE SECOND MOST PROMINENT CNS DISORDER, YET DESPITE THE WIDESPREAD AVAILABILITY OF EFFECTIVE ANTICONVULSANTS A LARGE PORTION OF THE PATIENT POPULATION STILL SUFFERS FROM INTRACTABLE SEIZURES. THEREFORE, THE DEVELOPMENT OF CEREBROPROTECTIVE AND NOVEL ANTICONVULSANT AGENTS IS URGENTLY NEEDED. A GROWING BODY OF EVIDENCE SUGGESTS THAT PHARMACOLOGICAL BLOCKADE OF NON-NMDA GLUTAMATE RECEPTORS, PRINCIPALLY KAINATE AND AMPA RECEPTORS, COULD PROVIDE SIGNIFICANT THERAPEUTIC BENEFIT IN THE TREATMENT OF SEIZURE DISORDERS AND THE PREVENTION OF NEURONAL DAMAGE AND DEATH. NOVA HAS IDENTIFIED PROPRIETARY COMPOUNDS POSSESSING KAINATE/AMPA RECEPTOR ANTAGONIST PROPERTIES AND HAS A MEDICINAL CHEMISTRYEFFORT DEVOTED TO THE SYNTHESIS OF NEWER COMPOUNDS. THE PRIMARY GOAL OF THE PHASE I PROJECT IS TO FURTHER CHARACTERIZE THESE COMPOUNDS AND WILL BE ACCOMPLISHED BY COMBINING IN VITRO ELECTROPHYSIOLOGY AND MOLECULAR BIOLOGY APPROACHES WITH IN VIVO BEHAVIORAL STUDIES. THE PURPOSE OF THESE STUDIES IS TO ASSESS THE THERAPEUTIC POTENTIAL OF NOVA'S KA/AMPA RECEPTOR ANTAGONISTS AS ANTICONVULSANT AND CEREBROPROTECTIVE AGENTS. STROKE IS THE MOST PROMINENT CNS DISORDER IN THE UNITED STATES AS WELL AS THE LEADING CAUSE OF DISABILITY AND THE THIRD LEADING CAUSE OF DEATH. HOWEVER, THERE ARE NO EFFECTIVE TREATMENTS AVAILABLE TO PREVENT OR REDUCE NEURONAL DAMAGE RESULTING FROM STROKE OR OTHER FORMS OF CEREBRAL ISCHEMIA. EPILEPSY IS THE SECOND MOST PROMINENT CNS DISORDER, YET DESPITE THE WIDESPREAD AVAILABILITY OF EFFECTIVE ANTICONVULSANTS A LARGE PORTION OF THE PATIENT POPULATION STILL SUFFERS FROM INTRACTABLE SEIZURES. THEREFORE, THE DEVELOPMENT OF CEREBROPROTECTIVE AND NOVEL ANTICONVULSANT AGENTS IS URGENTLY NEEDED. A GROWING BODY OF EVIDENCE SUGGESTS THAT PHARMACOLOGICAL BLOCKADE OF NON-NMDA GLUTAMATE RECEPTORS, PRINCIPALLY KAINATE AND AMPA RECEPTORS, COULD PROVIDE SIGNIFICANT THERAPEUTIC BENEFIT IN THE TREATMENT OF SEIZURE DISORDERS AND THE PREVENTION OF NEURONAL DAMAGE AND DEATH. NOVA HAS IDENTIFIED PROPRIETARY COMPOUNDS POSSESSING KAINATE/AMPA RECEPTOR ANTAGONIST PROPERTIES AND HAS A MEDICINAL CHEMISTRYEFFORT DEVOTED TO THE SYNTHESIS OF NEWER COMPOUNDS. THE PRIMARY GOAL OF THE PHASE I PROJECT IS TO FURTHER CHARACTERIZE THESE COMPOUNDS AND WILL BE ACCOMPLISHED BY COMBINING IN VITRO ELECTROPHYSIOLOGY AND MOLECULAR BIOLOGY APPROACHES WITH IN VIVO BEHAVIORAL STUDIES. THE PURPOSE OF THESE STUDIES IS TO ASSESS THE THERAPEUTIC POTENTIAL OF NOVA'S KA/AMPA RECEPTOR ANTAGONISTS AS ANTICONVULSANT AND CEREBROPROTECTIVE AGENTS.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government